La actividad tendrá lugar en el Refectorio de la Catedral de Pamplona y comenzará a las 19:00 h con una mesa redonda titulada “From Discovery to Impact: Exploring Navarra’s Health Innovation Ecosystem” en la que diferentes agentes compartirán su visión sobre el ecosistema biotecnológico y de innovación de Navarra.
La participación en esta jornada no tiene coste adicional para las personas inscritas en la XVIII SDDN Meeting, pero es necesario confirmar previamente la asistencia en sddn2026@sddn.es.
19:00 Registration and Networking
19:30 Bienvenida Institucional y mesa redonda “From Discovery to Impact: Exploring Navarra’s Health Innovation Ecosystem”
Jordi Quintana (SDDN): ecosistema nacional de drug discovery y desarrollo temprano de medicamentos.
Uxue Itoiz (CEIN): emprendimiento y crecimiento de startups innovadoras.
Iñaki Larraya Garayalde (SODENA): financiación e instrumentos de inversión para la innovación.
Ion Arrizabalaga (Polo IRIS): digitalización e IA para la competitividad empresarial.
Alicia López de Ocariz – Presidente de Navarra Health Cluster: El papel de los clústeres en la innovación y competitividad del sector salud.
20:10 Coctel and networking
09:00 – 09:30 Welcome and presentation of the XVIII SDDN Meeting (Assembly Hall, Science Library, University of Navarra)
09:30 – 11:00 Session 1: Drug Discovery Stories I
Chair: Ignacio Sancho (INBISTRA)
Juan Buela (SunRock Biopharma): The Business of Not Manufacturing Drugs: How to Become a Recurring Innovation Partner for the Pharmaceutical Industry.
Anabel Pérez (INBISTRA): A quick look at biotech portfolio choices.
Angel Lucio (Tetraneuron): Alzheimer’s Disease at a Turning Point: From Amyloid to Next-Generation Gene Therapy.
11:00 – 11:30 Coffee break, networking and one to one meetings session
11:30 – 12:00 Session 1: Drug Discovery Stories II
Roundtable with the 3 speakers of Session 1, moderated by Ignacio Sancho (INBISTRA)
13:15 – 14:30 Lunch, networking and one to one meetings session
14:30 – 16:30 Session 2 : Advanced Therapies
Chair: Juan José Lasarte (University of Navarra)
Annalaura Mastrangelo (CNIC – Centro Nacional de Investigaciones Cardiovasculares): Imidazole Propionate: From Multi-Omics Discovery to Therapeutic Targeting
Pablo Menendez (Instituto Josep Carreras – Sant Joan de Deu Hospital): Advancing CAR T-cell therapies in leukemia and sarcoma.
Alena Gros (Vall d’Hebron Institute of Oncology): Personalized T-Cell Therapies for Solid Cancers
Juan José Lasarte (University of Navarra): Outside the Box, Inside the Stroma: Targeting Non-Tumor Antigens and Metabolic Barriers to Boost immunotherapy
18:00 – 19:30 Poster session, mentoring and networking in the exhibitors’ area (Coffee and refreshments)
Chair: Rosario Fernández Godino (Medina Foundation)
Accelerate your future: Fast-track mentoring for early-career scientists . Join our fast-track mentoring session to connect for a few minutes with experts from academia and industry, get personalized advice, and accelerate your career with new ideas and connections.
18:30 – 20:00 One-to-one meetings session
All SDDN 2026 attendees will be invited to engage in one-to-one meetings, organized through a partnering platform.
21:00 Conference dinner.
9:00 – 10:00 Lessons from Young Leaders in Science and Innovation
A round table with early-career scientists, startup founders, and industry leaders who achieved remarkable success at a young age. Discover the decisions, challenges, and opportunities that shaped their journeys and what you can apply to your own career.
Chair: Rosario Fernández Godino (Medina Foundation)
Leire Escudero-Ibarz (AstraZeneca): Novel Drug Target Discovery Across Therapeutic Areas: Scaling Functional Genomics Powered by Multi-Omics and AI.
Aritz Lasarte (CIMA, Universidad de Navarra)
Francisco Ciriza (Quorum Biomedical)
10:00 – 10:30 Oral presentations of the selected posters
10:30 – 11:00 Coffee break and one to one meetings session
11:00 – 13:00 Session 3: Target and Biomarker Discovery
Chair: Leire Escudero-Ibarz (AstraZeneca)
Julen Oyarzábal (Columbus Venture Partners): Syngoi: From Market Need to Biotech Company through Synthetic Biology Innovation
Lorena Boquete (Galaria EPSS): From genome wide screening to protein-ligand modelling: uncovering targets for cancer cell adjuvanticity in a co-culture system.
Luis Serrano (Center for Genomic Regulation – CRG): Specific delivery of enhanced active biomolecules to treat lung diseases
Leire Escudero-Ibarz (AstraZeneca): Novel Drug Target Discovery Across Therapeutic Areas: Scaling Functional Genomics Powered by Multi-Omics and AI.
14:00 – 14:30 Closing remarks, poster awards ceremony, and announcement of the SDDN 2027 meeting
14:30 – 15:30 Lunch and networking
Presentations of SDDN partners and event sponsors I
Miriam Guadalupe Contreras Mostazo (Agilent): From Genomics to Cell Insights: Automated Solutions for Drug Discovery
Carmen Marangoni y Juan Pablo Tellez (Revvity): Monitoring ternary complex in cells, from manual to automatized workflows
Amarlig Helena Ferrigni (Paralab bio): Enabling the Drug Discovery Workflow: From Biophysics to In Vivo Imaging
Isreal Ramos (nNano): IRB Barcelona : Accelerating Drug Discovery Through Screening & Automation.
Alba Miguéns Gómez (MIBIOTRACE): Accelerating Drug Validation with Quantitative Imaging
Alessandro Taddei (Novalix): From Target to Candidate: One CRO partner across the Drug Discovery Journey
ASEBIO Representative: Impulsando el descubrimiento de fármacos desde la industria biotech
Presentations by SDDN partners and event sponsors II
Mariana Vaschetto (Collaborative Drug Discovery (CDD)): AI-Assisted Workflows for the Discovery of Gram-Negative Antibiotic
Alessandro Cinti (AXXAM): Harnessing Biology to Unlock New Paths in Drug Discovery
Maria Majellaro (Celtarys): Innovative Chemistry to illuminate biology: High Performance fluorescent probes to accelerate drug discovery
Alberto Parras Rodríguez (VivoXpand): Developing Science-Backed Products for Longevity Health Challenges
La Sesión de Pósteres, Mentoría y Networking en el Hall de Expositores ofrece una plataforma dinámica para que los asistentes interactúen con investigaciones de vanguardia, se conecten con mentores experimentados y amplíen sus redes profesionales. Esta sesión presentará una amplia variedad de pósteres científicos de investigadores emergentes y consolidados en el campo del descubrimiento de fármacos, fomentando un diálogo científico enriquecedor y la colaboración.
Además de explorar investigaciones innovadoras, los participantes tendrán la oportunidad de recibir orientación profesional y perspectivas a través de interacciones informales con líderes de la academia, la industria y el sector regulatorio.
Junto con la exhibición de pósteres de investigación innovadores de científicos en diferentes etapas de su carrera y las interacciones informales, la sesión incluye una actividad de Speed Mentoring diseñada para facilitar conversaciones enfocadas y eficientes en el tiempo entre investigadores en etapas iniciales y profesionales con experiencia. Esta oportunidad de mentoría estructurada permite a los participantes recibir consejos sobre trayectorias profesionales, desafíos de investigación y crecimiento profesional en un entorno de apoyo e informal.
La sesión también impulsa el networking a través de interacciones casuales, permitiendo a los asistentes establecer conexiones, explorar colaboraciones y obtener valiosas perspectivas sobre las tendencias emergentes en el descubrimiento de fármacos. El formato abierto e interactivo fomenta el intercambio interdisciplinario y está diseñado para apoyar tanto a científicos en etapas tempranas como a profesionales consolidados en el avance de su trabajo y en la construcción de vínculos duraderos.
Chair: Ignacio Sancho (INBISTRA)
Translating a breakthrough into a viable asset requires more than just good science; it demands a strategic “de-risking” mindset. This session explores the evolution of the biotech startup, focusing on the transition from academic innovation to investment-ready pipelines. We will dissect the current landscape of early-stage funding, the strategic utility of non-dilutive vs. dilutive capital, and the necessity of aligning preclinical milestones with clinical value inflection points.
Through a lens of operational discipline, we’ll discuss how founders can move beyond the “business plan” to build a dynamic strategic roadmap that survives market corrections and attracts the right partners. Whether you are navigating your first seed round or preparing for an IND, this session provides the playbook for bridging the gap between the bench and the bank.
Chair: Juan José Lasarte, Universidad de Navarra)
Artificial Intelligence (AI) is revolutionizing the development of new cancer immunotherapies, transforming traditional discovery into a high-precision engineering discipline. By leveraging deep learning and structural bioinformatics, AI allows researchers to navigate the complexity of the immune system with unprecedented accuracy, shifting the paradigm toward highly optimized and personalized therapeutic strategies. A primary application of AI is the design of personalized cancer vaccines. Computational algorithms are now essential for identifying tumor-specific neoantigens and predicting their binding affinity to MHC molecules. This enables the creation of bespoke vaccines tailored to a patient’s unique mutational landscape, maximizing immunogenicity while minimizing off-target effects.
Furthermore, AI is pivotal in the optimization of chimeric receptors for adoptive cell therapies. By refining receptor-antigen interactions and simulating synthetic logic gates, AI helps engineer CAR-T and TCR-T therapies that are more potent and resilient within the immunosuppressive tumor microenvironment. Finally, the design of optimized bispecific antibodies has been significantly accelerated by computational foresight.
This session will address these novel and rapidly evolving fields, which will likely define the development of future, optimized cancer therapies. By integrating computational intelligence into the drug discovery pipeline, we are setting a new standard of care in the global fight against cancer.
Chair: Leire Escudero-Ibarz (AstraZeneca)
The convergence of multi-omic technologies, complex disease models, and artificial intelligence is transforming target and biomarker discovery. This session explores how integrated approaches combining molecular profiling with functional validation in physiologically relevant systems enable identification of therapeutic targets and precision medicine biomarkers. Multi-omic profiling provides an unprecedented resolution of disease biology.
However, extracting actionable insights requires advanced integration strategies. AI and machine learning prioritize targets by identifying convergent evidence across molecular layers and patient data, while CRISPR screening in complex model systems enables functional validation of gene function.
This session will showcase disease-agnostic platforms and methodologies that bridge computational power with experimental validation. By demonstrating the synergy between multiomic integration, AI-driven analytics, and scalable functional genomics, the session will highlight how these approaches are accelerating novel therapeutic discoveries, enabling precision medicine strategies, and ultimately improving patient outcomes across diverse therapeutic areas.
¿Quieres saber más sobre nuestros socios protectores y patrocinadores?